Immunome, Inc. (NASDAQ:IMNM) CEO Clay B. Siegall Buys 137,100 Shares

Immunome, Inc. (NASDAQ:IMNM) CEO Clay B. Siegall purchased 137,100 shares of the business’s stock in a transaction on Wednesday, March 26th. The shares were purchased at an average cost of $7.29 per share, for a total transaction of $999,459.00. Following the transaction, the chief executive officer now directly owns 806,736 shares of the company’s stock, valued at approximately $5,881,105.44. The trade was a 20.47 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Immunome Trading Up 2.0 %

IMNM opened at $7.09 on Thursday. Immunome, Inc. has a 1-year low of $6.94 and a 1-year high of $26.70. The company has a market cap of $616.48 million, a price-to-earnings ratio of -0.87 and a beta of 1.93. The company’s fifty day moving average price is $9.61 and its two-hundred day moving average price is $11.41.

Immunome (NASDAQ:IMNM) last posted its earnings results on Wednesday, March 19th. The company reported ($0.84) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.16). The business had revenue of $2.74 million during the quarter, compared to analyst estimates of $3.07 million. Immunome had a negative return on equity of 48.63% and a negative net margin of 3,014.59%. As a group, equities analysts forecast that Immunome, Inc. will post -2.21 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of IMNM. BNP Paribas Financial Markets purchased a new stake in Immunome in the 4th quarter valued at $70,000. KLP Kapitalforvaltning AS purchased a new stake in shares of Immunome in the fourth quarter valued at about $75,000. AlphaQuest LLC lifted its position in shares of Immunome by 786,700.0% during the fourth quarter. AlphaQuest LLC now owns 7,868 shares of the company’s stock valued at $84,000 after purchasing an additional 7,867 shares in the last quarter. Tower Research Capital LLC TRC boosted its holdings in Immunome by 482.0% during the fourth quarter. Tower Research Capital LLC TRC now owns 8,608 shares of the company’s stock worth $91,000 after purchasing an additional 7,129 shares during the last quarter. Finally, Aquatic Capital Management LLC purchased a new position in Immunome during the fourth quarter worth about $95,000. Institutional investors own 44.58% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on IMNM. Stephens restated an “overweight” rating and set a $30.00 target price on shares of Immunome in a research report on Thursday, March 20th. Lifesci Capital started coverage on shares of Immunome in a research report on Tuesday, March 11th. They set an “outperform” rating and a $20.00 price objective for the company. Wedbush restated an “outperform” rating and issued a $33.00 price target on shares of Immunome in a report on Thursday, March 20th. Finally, Guggenheim cut their price objective on shares of Immunome from $35.00 to $25.00 and set a “buy” rating on the stock in a research report on Thursday, March 20th. Six research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $25.50.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.